FHL1 sirna

FHL1 siRNA (Mouse)

Cat. Num. AAA8224687

• Gene Names: Fhl1; KyoT; SLIM; FHL-1; SLIM-1; RAM14-1
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: FHL1; FHL1 siRNA (Mouse); Four and a half LIM domains protein 1; FHL-1; KyoT; RBP-associated molecule 14-1; RAM14-1; Skeletal muscle LIM-protein 1; SLIM; SLIM-1; FHL1 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: FHL1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 296

• Applicable Applications for FHL1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse FHL1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for FHL1 sirna

siRNA to inhibit FHL1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 116517336
• NCBI GeneID: 14199
• NCBI Accession #: NP_001070830.1
• NCBI GenBank Nucleotide #: NM_001077362.2
• UniProt Accession #: P97447; O55181; Q8K318
• Molecular Weight: 22,011 Da
• NCBI Official Full Name: four and a half LIM domains protein 1 isoform 2
• NCBI Official Synonym Full Names: four and a half LIM domains 1
• NCBI Official Symbol: Fhl1
• NCBI Official Synonym Symbols: KyoT; SLIM; FHL-1; SLIM-1; RAM14-1
• NCBI Protein Information: four and a half LIM domains protein 1
• UniProt Protein Name: Four and a half LIM domains protein 1
• Protein Family: Fork head transcription factor
• UniProt Gene Name: Fhl1
• UniProt Synonym Gene Names: FHL-1; RAM14-1; SLIM; SLIM-1
• UniProt Entry Name: FHL1_MOUSE

Uniprot Description

FHL1: May have an involvement in muscle development or hypertrophy. Defects in FHL1 are the cause of X-linked dominant scapuloperoneal myopathy (SPM). Scapuloperoneal syndrome (SPS) was initially described more than 120 years ago by Jules Broussard as 'une forme hereditaire d'atrophie musculaire progressive' beginning in the lower legs and affecting the shoulder region earlier and more severely than distal arm. The etiology of this condition remains unclear. Defects in FHL1 are the cause of X-linked myopathy with postural muscle atrophy (XMPMA). Myopathies are inherited muscle disorders characterized by weakness and atrophy of voluntary skeletal muscle, and several types of myopathy also show involvement of cardiac muscle. XMPMA is a distinct form of adult-onset X-linked recessive myopathy with several features in common with other myopathies, but the presentation of a pseudoathletic phenotype, scapuloperoneal weakness, and bent spine is unique and might render the clinical phenotype distinguishable from other myopathies. Defects in FHL1 are the cause of X-linked severe early- onset reducing body myopathy (RBM). RBM is a rare muscle disorder causing progressive muscular weakness and characteristic intracytoplasmic inclusions in myofibers. Clinical presentations of RBM have ranged from early onset fatal to childhood onset to adult onset cases. Defects in FHL1 are the cause of X-linked childhood-onset reducing body myopathy (CO-RBM). This disorder is allelic to severe early-onset reducing body myopathy (RBM). 5 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation

Cellular Component: focal adhesion; cytoplasm; plasma membrane; nucleus

Molecular Function: zinc ion binding; metal ion binding

Biological Process: multicellular organismal development; positive regulation of potassium ion transport; negative regulation of cell growth; cell differentiation